CN116271180A - Burn dressing - Google Patents
Burn dressing Download PDFInfo
- Publication number
- CN116271180A CN116271180A CN202310291217.1A CN202310291217A CN116271180A CN 116271180 A CN116271180 A CN 116271180A CN 202310291217 A CN202310291217 A CN 202310291217A CN 116271180 A CN116271180 A CN 116271180A
- Authority
- CN
- China
- Prior art keywords
- layer
- release layer
- burn
- drug delivery
- drug release
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims abstract description 42
- 229940079593 drug Drugs 0.000 claims abstract description 39
- 238000012377 drug delivery Methods 0.000 claims abstract description 37
- 239000003242 anti bacterial agent Substances 0.000 claims abstract description 30
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 14
- 239000008103 glucose Substances 0.000 claims abstract description 14
- 238000010521 absorption reaction Methods 0.000 claims abstract description 11
- 230000002745 absorbent Effects 0.000 claims abstract description 8
- 239000002250 absorbent Substances 0.000 claims abstract description 8
- 238000001514 detection method Methods 0.000 claims abstract description 7
- 239000000017 hydrogel Substances 0.000 claims description 15
- 229920001661 Chitosan Polymers 0.000 claims description 14
- 239000004327 boric acid Substances 0.000 claims description 11
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 claims description 10
- 239000004599 antimicrobial Substances 0.000 claims description 5
- 239000000126 substance Substances 0.000 claims description 5
- 239000002647 aminoglycoside antibiotic agent Substances 0.000 claims description 4
- 229940126574 aminoglycoside antibiotic Drugs 0.000 claims description 3
- 239000011148 porous material Substances 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 abstract description 12
- 239000010410 layer Substances 0.000 description 90
- 206010052428 Wound Diseases 0.000 description 57
- 208000027418 Wounds and injury Diseases 0.000 description 57
- 230000035876 healing Effects 0.000 description 14
- 210000000416 exudates and transudate Anatomy 0.000 description 10
- 230000009102 absorption Effects 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 6
- 230000000844 anti-bacterial effect Effects 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 230000002439 hemostatic effect Effects 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 230000029663 wound healing Effects 0.000 description 4
- RDEIXVOBVLKYNT-VQBXQJRRSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(1-aminoethyl)oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol;(2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2r,3r,6s)-3-amino-6-(aminomethyl)oxan-2-yl]o Chemical compound OS(O)(=O)=O.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@@H](CN)O2)N)[C@@H](N)C[C@H]1N.O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H](CC[C@H](O2)C(C)N)N)[C@@H](N)C[C@H]1N.O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N RDEIXVOBVLKYNT-VQBXQJRRSA-N 0.000 description 3
- FOIXSVOLVBLSDH-UHFFFAOYSA-N Silver ion Chemical compound [Ag+] FOIXSVOLVBLSDH-UHFFFAOYSA-N 0.000 description 3
- 206010048038 Wound infection Diseases 0.000 description 3
- 229940124350 antibacterial drug Drugs 0.000 description 3
- 229940088710 antibiotic agent Drugs 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 239000004745 nonwoven fabric Substances 0.000 description 3
- 230000008961 swelling Effects 0.000 description 3
- 241000192125 Firmicutes Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010040047 Sepsis Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000006978 adaptation Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000001804 debridement Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000000474 nursing effect Effects 0.000 description 2
- 229920006254 polymer film Polymers 0.000 description 2
- 238000010526 radical polymerization reaction Methods 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 206010051548 Burn infection Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 239000011837 N,N-methylenebisacrylamide Substances 0.000 description 1
- 206010039509 Scab Diseases 0.000 description 1
- 206010053692 Wound complication Diseases 0.000 description 1
- ULVXDHIJOKEBMW-UHFFFAOYSA-N [3-(prop-2-enoylamino)phenyl]boronic acid Chemical compound OB(O)C1=CC=CC(NC(=O)C=C)=C1 ULVXDHIJOKEBMW-UHFFFAOYSA-N 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 125000005619 boric acid group Chemical group 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 210000002744 extracellular matrix Anatomy 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- ZIUHHBKFKCYYJD-UHFFFAOYSA-N n,n'-methylenebisacrylamide Chemical compound C=CC(=O)NCNC(=O)C=C ZIUHHBKFKCYYJD-UHFFFAOYSA-N 0.000 description 1
- 238000012148 non-surgical treatment Methods 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 231100000075 skin burn Toxicity 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000002344 surface layer Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000002522 swelling effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000000472 traumatic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/00051—Accessories for dressings
- A61F13/00063—Accessories for dressings comprising medicaments or additives, e.g. odor control, PH control, debriding, antimicrobic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F13/02—Adhesive plasters or dressings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/24—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/22—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons containing macromolecular materials
- A61L15/28—Polysaccharides or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/46—Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00089—Wound bandages
- A61F2013/00157—Wound bandages for burns or skin transplants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00365—Plasters use
- A61F2013/00519—Plasters use for treating burn
- A61F2013/00523—Plasters use for treating burn with hydrogel
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00544—Plasters form or structure
- A61F2013/00604—Multilayer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61F—FILTERS IMPLANTABLE INTO BLOOD VESSELS; PROSTHESES; DEVICES PROVIDING PATENCY TO, OR PREVENTING COLLAPSING OF, TUBULAR STRUCTURES OF THE BODY, e.g. STENTS; ORTHOPAEDIC, NURSING OR CONTRACEPTIVE DEVICES; FOMENTATION; TREATMENT OR PROTECTION OF EYES OR EARS; BANDAGES, DRESSINGS OR ABSORBENT PADS; FIRST-AID KITS
- A61F13/00—Bandages or dressings; Absorbent pads
- A61F2013/00361—Plasters
- A61F2013/00902—Plasters containing means
- A61F2013/00906—Plasters containing means for transcutaneous or transdermal drugs application
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/23—Carbohydrates
- A61L2300/232—Monosaccharides, disaccharides, polysaccharides, lipopolysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
- A61L2300/406—Antibiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The present invention provides a burn dressing comprising: a backing layer; an absorbent layer positioned below the backing layer; the drug release layer is positioned below the absorption layer, and the detection limit of the drug release layer on glucose molecules is a preset value; the drug delivery layer is positioned below the drug release layer; and a release layer positioned below the drug delivery layer. The scheme of the invention can realize slow delivery of the antibacterial agent to the burn wound surface, thereby effectively preventing and treating infection of the burn wound surface.
Description
Technical Field
The invention relates to the technical field of dressing, in particular to a burn dressing.
Background
Accidental factors such as high temperature, current, chemicals and the like can cause skin burn, damage the integrity of the original structure of the skin, and damage the immune barrier. Shock, infection and multiple organ failure are three major complications of burn wounds, with the highest rate of mortality from infection. Bacteria can penetrate deep into the burn site and even expand the range of infection. The infection of the burn wound surface with large area can even cause septicemia, sepsis, microbial ecological unbalance of flora and the like, and cause great threat to the life health and the quality of life of patients.
Traditional methods of treating burn infections can be broadly divided into surgical and non-surgical treatments. The operation treatment mainly comprises the steps of cutting scab, debridement, autologous skin or allogenic skin transplantation and combining antibiotics to solve the infection problem; the non-operative treatment mainly comprises wound dressing covering wound surface, such as nanometer silver ion dressing, chitosan dressing, external antibacterial agent (antibiotic, natural antibacterial agent, etc.), and negative pressure sealing drainage technique. Because the healing time of the wound surface infected by burn is slow, the pure use of antibiotics can cause the unsatisfactory release time and speed of the medicine, thereby greatly reducing the effect of preventing the wound surface infection. In addition, the quality of treatment remains to be improved due to factors such as resistance caused by abuse of antibiotics, scar tissue after formation of poor healing, limited sources of autologous skin grafts, immunogenicity of allogenic skin, etc. The use of wound dressings such as nano silver ion dressing as a topical antibacterial drug for burn wounds has been over 50 years old, however nano silver ion dressing does not promote wound healing, and has potential safety hazards for other alternative antibacterial dressings; the chitosan dressing has the functions of bacteriostasis, hemostasis, healing promotion and pain relief, can promote the division of a plurality of functional cells such as epithelial cells, fibroblasts and the like and the growth of extracellular matrixes, obviously accelerates the healing of wound surfaces and reduces the formation of scars. However, the chitosan hydrogel film dressing has poor liquid absorption performance, so that the healing effect is poor, and meanwhile, the wound still has the risk of infection only by virtue of the antibacterial performance of the chitosan hydrogel film.
Therefore, the dressing in the prior art only has partial single efficacy, cannot have good antibacterial property, liquid absorption, analgesic property, hemostatic property and healing promotion, causes abuse of antibacterial drugs, and cannot meet the needs of patients.
Disclosure of Invention
The invention aims to solve the technical problem of providing a burn dressing which can realize slow delivery of an antibacterial agent to a burn wound surface so as to effectively prevent and treat infection of the burn wound surface.
In order to solve the technical problems, the technical scheme of the invention is as follows:
a burn dressing, comprising:
a backing layer;
an absorbent layer positioned below the backing layer;
the drug release layer is positioned below the absorption layer, and the detection limit of the drug release layer on glucose molecules is a preset value;
the drug delivery layer is positioned below the drug release layer; and
a release layer positioned below the drug delivery layer.
Optionally, the drug release layer is a semisolid substance with the viscosity of 50000-70000 mpa.s.
Optionally, the drug release layer is boric acid hydrogel.
Optionally, the drug release layer contains an antimicrobial agent.
Optionally, the antibacterial agent is an aminoglycoside antibiotic.
Optionally, the drug delivery layer is a chitosan film.
Optionally, the drug delivery layer is provided with holes with the aperture of 0.01-0.1 mm.
Optionally, the thickness of the drug delivery layer is 0.04-0.1 mm.
Optionally, the absorbing layer is sponge, non-woven fabric or medical gauze.
Optionally, the preset value is 1mg/L.
The scheme of the invention at least comprises the following beneficial effects:
the above-mentioned scheme of the invention, through the backing layer; an absorbent layer positioned below the backing layer; the drug release layer is positioned below the absorption layer, and the detection limit of the drug release layer on glucose molecules is a preset value; the drug delivery layer is positioned below the drug release layer; and a release layer positioned below the drug delivery layer. Thus, the antibacterial agent can be slowly delivered to the burn wound surface, thereby effectively preventing and treating infection of the burn wound surface.
Drawings
FIG. 1 is a schematic illustration of the construction of a burn dressing provided by an embodiment of the present invention;
fig. 2 is a schematic diagram showing slow delivery of an antibacterial agent after swelling of the drug release layer 3 and glucose molecules according to an embodiment of the present invention.
Detailed Description
Exemplary embodiments of the present disclosure will be described in more detail below with reference to the accompanying drawings. While exemplary embodiments of the present invention are shown in the drawings, it should be understood that the present invention may be embodied in various forms and should not be limited to the embodiments set forth herein. Rather, these embodiments are provided so that this disclosure will be thorough and complete, and will fully convey the scope of the invention to those skilled in the art.
As shown in fig. 1, an embodiment of the present invention provides a burn dressing comprising:
a backing layer 1; an absorbent layer 2 located under the backing layer 1; the drug release layer 3 is positioned below the absorption layer 2, and the detection limit of the drug release layer 3 on glucose molecules is a preset value; a drug delivery layer 4 positioned below the drug release layer 3; and a release layer 5 located below the drug delivery layer 4. Here, the release layer 5 may be release paper, which can protect the burn dressing, and ensure the viscosity of the burn dressing, so that the burn dressing can be firmly attached to the skin of the patient.
In the embodiment of the invention, the antibacterial agent can be slowly delivered to the burn wound surface by sequentially stacking the backing layer 1, the absorption layer 2, the drug release layer 3, the drug delivery layer 4 and the release layer 5, so that the infection of the burn wound surface can be effectively prevented and treated.
The dressing is applicable to nursing and isolating protection of chronic wounds, traumatic wounds, operation wounds and the like, inhibits bacteria, protects the wounds and promotes wound healing.
In an alternative embodiment of the invention, the drug release layer 3 is a semisolid substance having a viscosity of 50000-70000mpa.s (viscosity unit: millipascal-seconds).
In this embodiment, the viscosity of the semi-solid drug release layer 3 is 50000-70000mpa.s, so that the drug release layer 3 can be tightly attached to the absorption layer 2 and the drug delivery layer 4, and the drug release layer 3, the absorption layer 2 and the drug delivery layer 4 can fully play a role.
In yet another alternative embodiment of the present invention, the drug release layer 3 is a boric acid hydrogel.
In the embodiment, the boric acid hydrogel has excellent detection limit, can respond to glucose molecules in wound exudate, so that swelling effect is achieved, the aim of slowly delivering the antibacterial drug to burn wound surfaces of patients is fulfilled, and accordingly the release time and speed of the antibacterial agent reach ideal states.
It should be noted that the boric acid hydrogel can be prepared by photo-initiated free radical polymerization of 3-acrylamidophenylboronic acid, acrylamide, N, N-methylenebisacrylamide and photoinitiator as monomers.
In yet another alternative embodiment of the present invention, the drug release layer 3 contains an antimicrobial agent.
In this embodiment, the antibacterial agent can be released from the drug release layer 3 after swelling under the action of glucose molecules in the drug release layer 3 and wound exudate, and is slowly delivered to the burn wound through the drug delivery layer 4, so as to promote the healing of the wound.
The antibacterial agent is dispersed in the prepolymer of the boric acid hydrogel, and is immobilized in the hydrogel matrix by photoinitiated radical polymerization.
In yet another alternative embodiment of the present invention, the antimicrobial agent is an aminoglycoside antibiotic.
In this embodiment, the antimicrobial agent may include, but is not limited to: gentamicin sulfate; gentamicin sulfate has broad-spectrum antibiotic effect on gram-positive bacteria and gram-negative bacteria, can perform antibacterial treatment on burn wound surfaces, and avoids wound surfaces from being infected.
In yet another alternative embodiment of the present invention, the drug delivery layer 4 is a chitosan film.
In this embodiment, the chitosan film has the properties of easing pain, stopping bleeding and promoting healing, can accelerate the healing of the wound surface, has the washing liquid property, can realize the drainage of the wound exudate, and enables the drug delivery layer 4 to drain the wound exudate to the drug release layer 3 to act, so that the drug release layer 3 swells and releases the antibacterial agent, and the antibacterial agent is slowly delivered to the wound surface through the drug delivery layer 4, thereby promoting the healing of the wound surface.
The chitosan film may be a mixture of chitosan and glycerin.
In yet another alternative embodiment of the present invention, the drug delivery layer 4 is provided with holes with a hole diameter of 0.01-0.1 mm.
In this embodiment, the wound exudate can pass through the holes on the drug delivery layer 4, and can be swelled and released with the drug release layer 3, and the antibacterial agent can be delivered to the burn wound, so that the infection of the wound can be effectively prevented and treated.
In yet another alternative embodiment of the present invention, the thickness of the drug delivery layer 4 is 0.04-0.1 mm.
In this embodiment, when the antibacterial agent is released from the drug release layer 3, the antibacterial agent needs to be gradually delivered to the burn wound surface layer by layer through the drug delivery layer 4, and the thickness of the drug delivery layer 4 is set to be 0.04-0.1 mm, so that the requirement of slowly delivering the antibacterial agent to the burn wound surface can be met.
In yet another alternative embodiment of the present invention, the absorbent layer 2 is a sponge, a nonwoven fabric or a medical gauze.
In this embodiment, the dressing core of the absorbent layer 2 may include, but is not limited to: sponge, non-woven fabric or medical gauze; the exudate of the burn wound of the patient can be absorbed through the absorption layer 2, so that the cleanness of the burn wound of the patient is ensured, the wound infection is avoided, the antibacterial agent released by the medicine release layer 3 can fully treat the wound, and the healing of the wound is promoted.
In yet another alternative embodiment of the present invention, the preset value is 1mg/L.
In this embodiment, the drug release layer 3 may be a boric acid hydrogel, the limit of detection of the boric acid hydrogel on glucose molecules is 1mg/L, and the boric acid hydrogel has a remarkable response on glucose molecules under the condition of ph=6.0-7.5, so that the glucose molecules and the boric acid hydrogel fully act, the drug release layer 3 swells to release the antibacterial agent, and the antibacterial agent is slowly delivered to the wound surface through the drug delivery layer 4, so as to promote wound healing.
As shown in fig. 2, wound exudate is drained to the drug delivery layer 3 through the drug delivery layer 4, so that the drug delivery layer 3 acts with glucose molecules in the wound exudate and swells, and the antibacterial agent in the drug delivery layer 3 is slowly released from the hydrogel matrix of the drug delivery layer 3 to the outside of the matrix in the direction a shown by an arrow, and is slowly delivered to the wound through the drug delivery layer 4, thereby promoting wound healing, and it is to be noted that a black filled circle in fig. 2 represents the antibacterial agent.
It is worth noting that the larger the area of the wound surface is, the more the number of glucose molecules in exudates or blood is, the faster the swelling rate of the drug release layer 3 is, and the faster the release rate of the antibacterial agent is, and the slow delivery of the antibacterial agent to the wound surface can be realized due to the 0.04-0.1 mm aperture of the drug delivery layer 4, so that the prevention and treatment of wound infection can be realized.
The application method of the burn dressing provided by the invention comprises the following steps:
the conventional debridement is carried out, the inner packaging bag is opened in a sterile operation, the burn dressing is taken out, the stripping layer 5 is torn off, the burn dressing is tightly attached to the wound surface, and the dressing is lightly pressed for about 1 minute, so that the bonding of the dressing to the wound surface is firmer; if a large amount of exudates exist on the wound surface, the wound surface needs to be replaced in time, and the wound surface needs to be cleaned every time the wound surface is replaced; the burn dressing is sterilized to meet the aseptic requirement, and secondary pollution should be avoided in the use process.
The hemostatic principle of the burn dressing of the invention comprises:
the medicine delivery layer 4 is a chitosan film, and the chitosan film has active amino groups, can aggregate red blood cells and concentrate platelets, and realizes the hemostatic function without depending on a conventional blood coagulation way.
The bacteriostasis principle of the burn dressing provided by the invention comprises the following steps:
the active amino group in the drug delivery layer 4 can be combined with negatively charged substances in the bacterial body, such as milk protein and nucleic acid, so that the normal physiological functions of cells are influenced to die, or a layer of polymer film is formed on the surface of the bacterial cells by adsorption, so that the permeability of the polymer film is changed to cause cell death;
the gentamicin sulfate of the bacteriostatic agent in the drug release layer 3 is aminoglycoside antibiotics, and has broad-spectrum antibiotic action on bacteria such as gram positive bacteria, gram negative bacteria and the like by interfering with the protein synthesis of the bacteria; based on the synergistic antibacterial effect of the chitosan film and the antibacterial agent, the effect of the burn dressing on preventing and treating burn wound infection is obviously improved.
In the embodiment of the invention, the burn dressing has a simple and practical structure, can reduce the workload of nursing staff and improve the satisfaction of patients; the boric acid hydrogel is contacted with glucose molecules in the seepage liquid to swell so as to slowly release the antibacterial agent, thereby being beneficial to promoting the healing of wound surfaces; in addition, the chitosan film has healing promotion, pain relieving and hemostatic properties, adjusts the inflammation microenvironment of the burn wound based on the synergistic effect of the two, maintains the balance of wound seepage, reduces the action pathways such as wound pain and the like, and accelerates the healing of the wound.
While the foregoing is directed to the preferred embodiments of the present invention, it will be appreciated by those skilled in the art that various modifications and adaptations can be made without departing from the principles of the present invention, and such modifications and adaptations are intended to be comprehended within the scope of the present invention.
Claims (10)
1. A burn dressing, comprising:
a backing layer (1);
an absorbent layer (2) located under the backing layer (1);
the drug release layer (3) is positioned below the absorption layer (2), and the detection limit of the drug release layer (3) on glucose molecules is a preset value;
a drug delivery layer (4) positioned below the drug release layer (3); and
and a release layer (5) positioned below the drug delivery layer (4).
2. Burn dressing according to claim 1, wherein the drug release layer (3) is a semisolid substance with a viscosity of 50000-70000 mpa.s.
3. Burn dressing according to claim 2, wherein the drug release layer (3) is a boric acid hydrogel.
4. A burn dressing according to any one of claims 1 to 3, wherein the drug release layer (3) contains an antibacterial agent.
5. The burn dressing of claim 4 wherein the antimicrobial agent is an aminoglycoside antibiotic.
6. Burn dressing according to claim 1, wherein the drug delivery layer (4) is a chitosan film.
7. Burn dressing according to claim 6, characterized in that the drug delivery layer (4) is provided with holes with a pore size of 0.01-0.1 mm.
8. Burn dressing according to claim 1, wherein the thickness of the drug delivery layer (4) is 0.04-0.1 mm.
9. Burn dressing according to claim 1, characterized in that the absorbent layer (2) is a sponge, a nonwoven or a medical gauze.
10. The burn dressing of claim 1 wherein the preset value is 1mg/L.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310291217.1A CN116271180A (en) | 2023-03-23 | 2023-03-23 | Burn dressing |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310291217.1A CN116271180A (en) | 2023-03-23 | 2023-03-23 | Burn dressing |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN116271180A true CN116271180A (en) | 2023-06-23 |
Family
ID=86830339
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310291217.1A Pending CN116271180A (en) | 2023-03-23 | 2023-03-23 | Burn dressing |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116271180A (en) |
-
2023
- 2023-03-23 CN CN202310291217.1A patent/CN116271180A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nuutila et al. | Moist wound healing with commonly available dressings | |
| Gruppuso et al. | Polymeric wound dressings, an insight into polysaccharide-based electrospun membranes | |
| Kannon et al. | Moist wound healing with occlusive dressings: a clinical review | |
| Kus et al. | Wound dressings–a practical review | |
| Agarwal et al. | Polymeric materials for chronic wound and burn dressings | |
| HU225557B1 (en) | Absorbent wound dressing containing a hydrogel layer | |
| Yang et al. | A review on antimicrobial silver absorbent wound dressings applied to exuding wounds | |
| KR20240008975A (en) | Wound dressing | |
| WO2023198086A1 (en) | Antibacterial healing-promoting functionalized dressing and preparation method therefor | |
| CN114732936A (en) | High-air-permeability degradable drug-loaded skin wound dressing | |
| Jacobsen | Update on wound dressings: indications and best use | |
| Thomas | 12 Wound Dressings | |
| Carter | Hydropolymer dressings in the management of wound exudate | |
| CN111557790A (en) | Antibacterial and disinfectant nanofiber medical dressing | |
| CN116271180A (en) | Burn dressing | |
| Walker et al. | Hydrofiber® Technology: its role in exudate management | |
| Sarheed et al. | Honey products and their potential in wound healing | |
| RU2240140C2 (en) | Medicinal multilayer bandage and articles based on such bandage | |
| Green | Making an informed decision: how to choose the correct wound dressing: wound care | |
| Sonar et al. | A Comprehensive review on wound dressing usage in clinical settings | |
| Foutsizoglou | A practical guide to the most commonly used dressings in wound care | |
| Rizani | Modern Wound Dressing for Wound Infection: An Overview | |
| RU2247580C2 (en) | Layered material with prolonged therapeutical effect for treating wounds, burns, and bedsores as well as for providing first medical aid | |
| RU2198685C1 (en) | Medicinal polymeric gel material and curative preparations made upon its basis | |
| Lau | What dressing: New wound dressings |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |